Evidence map›Paper›PMID 35883700›Full record

ArticleCells2022

TRPM7 Modulates Human Pancreatic Stellate Cell Activation.

Julie Auwercx, Philippe Kischel, Thibaut Lefebvre, Nicolas Jonckheere, Alison Vanlaeys, Stéphanie Guénin, Silviya Radoslavova, Isabelle Van Seuningen, Halima Ouadid-Ahidouch, Hemant M Kocher and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Role of TRPM7 in Oncogenesis.International journal of molecular sciences · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Julie AuwercxUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.ORCID 0000-0002-5873-4838
Philippe KischelUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.ORCID 0000-0001-7201-2797
Thibaut LefebvreUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.
Nicolas JonckheereUniversité Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.ORCID 0000-0002-0496-0661
Alison VanlaeysUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.
Stéphanie GuéninCentre de Ressources Régionales en Biologie Moléculaire, Université de Picardie Jules Verne, F-80039 Amiens, France.ORCID 0000-0002-0514-982X
Silviya RadoslavovaUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.
Isabelle Van SeuningenUniversité Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.ORCID 0000-0002-3131-2694
Halima Ouadid-AhidouchUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.
Hemant M KocherCentre for Tumour Biology, Barts Cancer Institute-A CRUK Centre of Excellence, Queen Mary University London, London EC1M 6BQ, UK.ORCID 0000-0001-6771-1905
Isabelle Dhennin-DuthilleUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.ORCID 0000-0003-1273-3511
Mathieu GautierUR-UPJV 4667, UFR des Sciences, Université de Picardie Jules Verne, F-80039 Amiens, France.ORCID 0000-0001-8971-5683
Laboratoire de physiologie cellulaire et moléculaire · FRCentre National de la Recherche Scientifique · FRQueen Mary University of London · GBUniversité de Picardie Jules Verne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic diseases, such as pancreatitis or pancreatic ductal adenocarcinoma, are characterized by the presence of activated pancreatic stellate cells (PSCs). These cells represent key actors in the tumor stroma, as they actively participate in disease development and progression: reprograming these PSCs into a quiescent phenotype has even been proposed as a promising strategy for restoring the hallmarks of a healthy pancreas. Since TRPM7 channels have been shown to regulate hepatic stellate cells proliferation and survival, we aimed to study the role of these magnesium channels in PSC activation and proliferation. PS-1 cells (isolated from a healthy pancreas) were used as a model of healthy PSCs: quiescence or activation were induced using all-trans retinoic acid or conditioned media of pancreatic cancer cells, respectively. The role of TRPM7 was studied by RNA silencing or by pharmacological inhibition. TRPM7 expression was found to be correlated with the activation status of PS-1 cells. TRPM7 expression was able to regulate proliferation through modulation of cell cycle regulators and most importantly p53, via the PI3K/Akt pathway, in a magnesium-dependent manner. Finally, the analysis of TCGA database showed the overexpression of TRPM7 in cancer-associated fibroblasts. Taken together, we provide strong evidences that TRPM7 can be considered as a marker of activated PSCs.

Indexed as

Pancreatic NeoplasmsTRPM Cation ChannelsHumansMagnesiumPancreatic Stellate CellsPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesMagnesiumPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesTRPM7 protein, humanTRPM Cation Channelscancerpancreatic stellate cellsTRPM7

Identifiers

PMID35883700
PMCPMC9316618
OpenAlexW4286492740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.